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Background: The extent to which metastatic tumors further evolve by accumulating additional mutations is unclear
and has yet to be addressed extensively using next-generation sequencing of high-grade serous ovarian cancer.
Methods: Eleven spatially separated tumor samples from the primary tumor and associated metastatic sites and two
normal samples were obtained from a Stage IIIC ovarian cancer patient during cytoreductive surgery prior to
chemotherapy. Whole exome sequencing and copy number analysis were performed. Omental exomes were
sequenced with a high depth of coverage to thoroughly explore the variants in metastatic lesions. Somatic mutations
were further validated by ultra-deep targeted sequencing to sort out false positives and false negatives. Based on the
somatic mutations and copy number variation profiles, a phylogenetic tree was generated to explore the evolutionary
relationship among tumor samples.
Results: Only 6% of the somatic mutations were present in every sample of a given case with TP53 as the only known
mutant gene consistently present in all samples. Two non-spatial clusters of primary tumors (cluster P1 and P2), and a
cluster of metastatic regions (cluster M) were identified. The patterns of mutations indicate that cluster P1 and P2
diverged in the early phase of tumorigenesis, and that metastatic cluster M originated from the common ancestral
clone of cluster P1 with few somatic mutations and copy number variations.
Conclusions: Although a high level of intratumor heterogeneity was evident in high-grade serous ovarian cancer, our
results suggest that transcoelomic metastasis arises with little accumulation of somatic mutations and copy number
alterations in this patient.
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Transcoelomic metastasisBackground
Epithelial ovarian cancer is the fifth leading cause of
cancer death among women in the USA [1]. The major
reason for the poor prognosis is the fact that more than
75% of patients are diagnosed with advanced stage dis-
ease characterized by metastasis to the peritoneal cavity.
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coelomic is the most common route of metastasis in epi-
thelial ovarian cancer and contributes to the significant
morbidity and mortality associated with this cancer [2].
Given the high recurrence rate and poor long-term sur-
vival of women with advanced stage disease, there is a
strong need to document the unique metastatic patterns
of epithelial ovarian cancer by comparing the differences
in genetic profiles between primary and metastatic lesions.
With the recent development of next-generation se-
quencing (NGS) technology, the Cancer Genome Atlas
(TCGA) researchers have identified molecular abnormal-
ities related to the pathophysiology, clinical outcome, andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer (HGSC) [3]. The TCGA study provides a large-
scale integrative view of the aberration in HGSC with
extensive heterogeneity between individual tumors. How-
ever, it is not certain whether the genomic alterations
found in single tumor biopsy samples from primary tu-
mors are maintained in metastatic lesions. Furthermore,
intratumor heterogeneity has been proposed as the main
cause of treatment failure and drug resistance in ovarian
cancer and other primary cancers [4]. Recently, NGS tech-
nology has led to progress in the evaluation of intratumor
heterogeneity in various cancers [5-8]. In the field of
HGSC, intratumor heterogeneity has been evaluated
within primary tumors and associated metastatic sites,
and the divergence of genetic variants was observed [5].
Despite evident intratumor heterogeneity within individual
patients, little is known about how metastatic tumors fur-
ther evolve compared to primary sites. The aim of this
study was to explore the mutational profiles of primary tu-
mors and associated metastatic lesions, and to identify the
evolutionary relationship between primary and metastatic
clones with NGS technology.
Methods
Patient information and sample preparation
A 71-year-old female was diagnosed with stage IIIC ovar-
ian cancer at the time of sample collection. She had no
family history for breast or ovarian cancer. She underwent
BRCA1/2 germline mutation testing (Integrated BRACA-
nalysis®) and no mutation was found. Preoperative CA-125
level was 336 U/mL. She underwent cytoreductive surgery
followed by platinum-based chemotherapy. During cytore-
ductive surgery, a right ovarian cystic mass of 10 × 9 ×
8 cm in size was found. Multiple solid lesions were found
inside the right ovarian cystic mass. A left ovarian tumor
measuring 6 × 5 × 4 cm and consisting mostly of solid tis-
sue was also found. Seven samples were taken randomly
from the solid portions of both ovaries with a certain dis-
tance retained between each sample. All tissues consisted
of >70% high-grade (FIGO grade 3) serous adenocarcin-
oma cells based on pathological review. Adjacent normal
tissues from the left fimbriae and blood were also collected
to serve as normal controls. Eleven tumor samples were
collected from the ovaries, right fimbriae, bladder periton-
eum, and omental lesions during surgery under the super-
vision of our pathologist (Min A Kim) (Figure 1A).
This patient had no evidence of recurrence at the time of
publication and 12 months had passed since the comple-
tion of first-line treatment. This was a platinum-sensitive
case (>6 months after first-line treatment completion). This
study was approved by the Institutional Review Board (IRB)
at Seoul National University Hospital (Registration number:
C-1305-546-487) and performed in compliance with the
Helsinki Declaration. We obtained informed consent forsamples to be used in research. Written informed consent
was obtained from the patient for publication of the case
report including any accompanying images and disclosure
of sequence data.
Library construction, exome capture, and sequencing
Genomic DNA was extracted separately from each sam-
ple (Qiagen, Valencia, CA, USA) and shotgun libraries
were constructed by shearing 3 μg of genomic DNA.
The SureSelect Human All Exon V4 + UTRs kit (Agilent,
Santa Clara, CA, USA) was used to capture 71 Mbps of
exons and UTRs, according to the manufacturer’s proto-
col, which were subsequently sequenced on an Illumina
HiSeq2500 (Additional file 1: Tables S1 and S2). Sequen-
cing data are accessible at Sequence Read Archive (SRA,
accession number SRS823287).
Analysis of whole exome sequencing data
Short reads were aligned to the reference human gen-
ome (hg19) using Novoalign V2.07.18 with the default
options. PCR and optical duplicates were removed using
Picard v1.67 MarkDuplicates. Local realignment around
the known indels in dbSNP135 and base quality score
recalibration were performed using the Genome Ana-
lysis Toolkit (GATK) v2.6-4 [9]. Somatic mutations were
identified by muTect 1.1.4 with the default options [10],
and manually inspected by using Integrative Genome
Viewer (IGV) [11]. The variants were annotated using
the SeattleSeq Annotator, and then the variants listed in
dbSNP132 and in repetitive regions were removed
(repeatMasker, tandemRepeat column in SeattleSeq). In-
tronic, intergenic, near-gene, and synonymous mutations
were also excluded. The germline mutations were identi-
fied by the GATK Unified Genotyper with the blood
sample. Small indels were detected by Dindel v1.01 [12].
To avoid false positive somatic indels, only indels validated
manually by IGV and confirmed by multiplex PCR were
considered real variants. Candidate driver mutations and
functional germline mutations were called based on the
results from seven functional prediction algorithms and
three conservation score algorithms using ANNOVAR
[13] and dbNSFP v2.0 [14] (Additional file 2). All URLs
for the analysis programs are listed in Additional file 2.
Somatic copy number alteration (SCNA) analysis
Genomic DNA (~600 ng) from each sample was proc-
essed with SNP chip analysis using the Genome-wide
Human SNP Array 6.0 (Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s instructions
(Additional file 1: Table S1). Raw data were processed
with the Affymetrix SNP6 Copy Number Inference
Pipeline developed by Broad Institute using GenePat-
tern modules [15]. Briefly, raw data was calibrated to
signal intensities, called genotypes, and then the signal
Figure 1 Intra-tumoral mutational profiles of HGSC. (A) Sampling sites of tumor and normal control tissues. (B) Phylogenetic tree of somatic
mutations. (C) Phylogenetic tree of somatic copy number variations. (D) Patterns of somatic mutations across samples. HGSC: high grade serous
ovarian cancer, RO: right ovary, RF: right fimbriae, LO: left ovary, LF: left fimbriae, BP: bladder peritoneum, OM: omentum.
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refinement of the copy numbers, somatic copy number
alterations (SCNA) were called by subtracting the sig-
nals in the tumor sample from those in the normal
sample. The segments of the SCNA were identified by
circular binary segmentation.For omental samples, whole exome sequencing data was
used to detect SCNA. Pair-end read data was processed by
the Varscan2 copynumber and copyCaller [16] with whole
exome sequencing data of blood and the following non-
default parameters: max-segment-size, 250; data-ratio 0.301
for OM1 and 0.306 for OM2. These raw segment data were
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[17] with alpha = 0.01, nperm = 10,000, and trim = 0.025,
then the segment values were magnified three times. All
SCNA were visualized using Circos plot v0.64 [18].
Validation of somatic mutations and indels
Since quality control for false negatives is crucial for ex-
ploring intratumor heterogeneity, we selected 122 loci
primers for multiplex PCR with HiSeq2500 for valid-
ation. Primer pairs were designed and synthesized based
on column-based methods, pooled, and multiplex PCR
was performed with 50 ng of genomic DNA from each
sample (Celemics, Seoul, Korea). Subsequently, each prod-
uct was indexed, mixed, and deeply sequenced on
HiSeq2500. Raw data was deindexed and mapped to the
reference human genome (hg19) using NovoAlign. Muta-
scope was used to call somatic mutations, and compared
to the whole exome sequencing data [19]. Only the loci
with at least 500 reads of both normal and tumor tissue
and >5% allelic fraction were used for validation.Phylogenetic tree construction and variant classification
A phylogenetic tree was generated to assess the tumor
evolutionary patterns in terms of somatic mutations.
The phylogenetic analysis followed the method described
in a previous report [5]. All point mutations were con-
verted to binary data (0 = no mutation, 1 = somatic mu-
tation) for each sample, and a matrix with sample names
in rows and loci in columns was generated. Next, we cal-
culated Pearson correlation coefficients (ρxy) between
samples x and y, and 1-ρxy was considered the distance
between x and y. The Neighbor-Joining method [20] and
the Unweighted Pair Group Method with Arithmetic
Mean (UPGMA) method were applied to cluster sam-
ples and construct the phylogenetic tree. We used the
‘ape’ R package [21] for these analyses.
Samples were segregated by cluster P1, cluster P2, and
cluster M for further analysis (Figure 1). If any somatic
mutation was found in at least three samples in ‘cluster
P1’ or at least two samples in ‘cluster P2’ and ‘cluster M’,
we concluded that the mutation truly existed in that re-
spective cluster. A mutation was classified as “Common”
when it was found in all clusters, as “Shared” when found
in any two clusters, as “Cluster-specific” when found in
only one cluster, otherwise as “Sample-specific”.
Similar to the somatic mutation analysis, somatic copy
number alterations were also converted to weights as
follows; δmax [log10 L, 1], where L is the segment
length, δ = 1 if the segment was amplified, −1 if deleted,
or 0 otherwise. A matrix with sample names in rows and
altered regions in columns were constructed. Pearson
coefficients were calculated, and a phylogenetic tree was
generated as described above.The segments were classified as cluster P1, cluster P2,
and cluster M as well. Initially, the cut-off values (log2
ratio) for amplified and deleted segments were set to 0.2
and −0.2, respectively. We decided that the segment was
altered, either amplified or deleted, only if all samples in
each cluster were amplified or all samples were deleted.
If any sample in a cluster was altered differently, the seg-
ment was neglected. We classified the segments as
“Common” when all three clusters had the same sample
variation, “Shared” when any two clusters had the same
variation, and “Specific” when variation was found in
only one cluster. Coding genes (RefSeq database) within
each segment were collected and functional analysis was
performed using the DAVID functional annotation tool
[22] and the GO_BP (Gene Ontology, Biological Process)
and KEGG pathway databases.
Results
Whole coding exons and untranslated regions (71 Mbp)
in genomic DNA from seven ovarian tumor sites, three
metastatic lesions, and two normal control samples (in-
cluding a blood sample) were sequenced (Figure 1A).
The mean coverage was 92× for tumor tissue and 65×
for normal tissue. We sequenced more deeply on two
omental tumor samples (211×, 199×) to thoroughly ex-
plore the variants in metastatic lesions (Additional file 1:
Table S2). A total of 2,248 somatic mutations (3.2/Mb
for each sample on average) were identified, and the
average number of non-synonymous or splicing site mu-
tations was 122 per sample (range: 77–167) (Additional
file 1: Table S3). To avoid overestimation of intratumor
heterogeneity, we randomly selected 122 somatic muta-
tions (Additional file 1: Table S4) and performed multi-
plex PCR followed by ultra-deep re-sequencing (median
coverage: 9,647×) for eight samples (Additional file 1:
Table S1). The precision, false negative rate, and false posi-
tive rate of mutation calling in whole exome sequencing
were 93%, 6%, and 1%, respectively. We found no patho-
logic BRCA1 and BRCA2 germline mutation in this pa-
tient. Other germline mutations are listed in Additional
file 1: Table S5.
Phylogenetic trees were generated with somatic muta-
tion data on 634 loci that were found at least once in
the tumor samples. The samples from primary sites were
segregated into two clusters (clusters P1 and P2), and
the samples from metastatic lesions formed cluster M
(Figure 1B). Based on the evolutionary tree, clusters P1
and P2 diverged earlier than cluster P1 and M. Interest-
ingly, clusters P1 and P2 were not united according to
the spatial position of sampling sites. These patterns
were also observed in the phylogenetic tree based on
copy number variations (Figure 1C).
Next, we classified 313 non-synonymous or splicing site
mutations into four groups: Common, Shared, Cluster-
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tions (6%) were found in most samples, the Common
group, which showed higher intratumor heterogeneity
than previous studies across various cancers [5-8]. Ten
non-synonymous mutations in genes including TP53,
KIF13A, and SPIC were identified (Table 1), indicating that
those mutations were acquired in the early stage of
tumorigenesis. Eighty-two (26%) somatic mutations were
in the Shared group. All mutations in the Shared group
were discovered in both cluster P1 and cluster M, support-
ing a common evolutionary origin. Also, 25 nonsynon-
ymous mutations were considered as the candidate driver
mutations. TP53 Y220C and SPIC E152K in the Common
group are only mutations listed in COSMIC database
(Table 1). We could not identify any anti-neoplastic thera-
peutic agents that interact with candidate driver mutations
except PRKCQ C281S, which was found to interact withTable 1 Candidate driver mutations affecting characteristics o
Type Genomic position (hg19) Base change Gene
Common
chr17:7578190 T>C TP53
chr6:17781485 C>T KIF13A
chr14:25044511 G>A CTSG
chr15:92459643 T>C SLCO3A
chr12:101880256 G>A SPIC
Shared (P1, M)
chr10:28905209 T>G WAC
chr14:24879362 G>T NYNRIN
chr21:37710167 G>T MORC3
chr1:154184966 C>G C1orf43
chr4:154626187 A>G TLR2
chr12:52183202 G>C SCN8A
chr14:23886761 G>C MYH7
chr1:11594572 G>A PTCHD2
chr12:20799431 C>A PDE3A
chr2:196545035 G>T SLC39A
Cluster P1-specific
chr1:43317062 T>G ZNF691
chr13:113893782 G>T CUL4A
chr6:117892084 C>A GOPC
chr11:134090616 C>A NCAPD
Cluster M- specific
chr1:206944347 T>C IL10
chr2:242690697 C>G D2HGD
Cluster P2-specific
chr15:80866542 C>G ARNT2
chr8:72211468 C>G EYA1
chr3:101371645 T>G ZBTB11
chr10:6528056 A>T PRKCQ
†Predicted as damaging = (the number of algorithms predicting a damaging mutati
cutoffs were described in the Methods.
*Stop codon.
N/A = not available.sophoretin [23]. However, this mutation is only detected
in Cluster P2.
Only 11 somatic mutations were identified in the
Cluster-specific group in cluster M, much fewer than
those in clusters P1 and P2 (39 and 54, respectively). The
mutations classified in cluster M-specific group were
dominantly found in most samples of cluster M but not in
other clusters. However, all 11 cluster M-specific muta-
tions were also found in at least one sample from cluster
P1. In contrast, most cluster P2-specific mutations were
found only in cluster P2 (Figure 1D). False negative calling
of cluster M-specific mutations was less likely, since the
omental samples were deeply exome-sequenced and fur-
ther validated by multiplex PCR followed by deep re-
sequencing. The false negative rate of mutation calling in
omental samples calculated with validation sequencing
was less than 10%. Therefore, it seems that cluster Mf ovarian cancer
Amino acid change Predicted as damaging† COSMIC (ID)
Y220C 7/7 COSM99720
G1198S 6/7 -
R55* N/A -
1 Y201H 6/7 -
E152K 2/7 COSM458288
L555* N/A -
G788* N/A -
G128V 6/7 -
D159H 6/7 -
S710G 6/7 -
K1432N 6/7 -
S1435C 6/6 -
W1170* N/A -
N753K 6/7 -
10 G90V 6/7 -
C176G 6/7 -
D318Y 6/7 -
G276V 6/7 -
3 W23C 6/7 -
M95V 5/7 -
H S345C 7/7 -
S457* N/A -
D214H 7/7 -
H816P 7/7 -
C281S 7/7 -
on)/(the number of available algorithms). The prediction algorithms and their
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with few additional somatic mutations.
To identify the branching mutation related to the ori-
gin of cluster P2, we focused on a subset of cluster P2-
specific mutations found in non-cluster P2 samples
(Additional file 1: Table S6). The allele frequency of each
sample determined by ultra-deep re-sequencing was nor-
malized to the mean allele frequency. The normalized al-
lele frequencies were comparable between cluster P2
and non-cluster P2 samples, but that of ARNT2 S457* in
cluster P2 was about ten-fold higher than in the right
fimbriae. This finding supports the notion that the mu-
tation was obtained upon the divergence of cluster P2.
SCNA were derived from six tumor samples and a
normal sample. The analysis showed that the genomic
architectures of samples in cluster M were similar to the
patterns in cluster P1, but an arm-scale deletion on
chromosome X was observed in cluster M (Figure 2). In
contrast, the copy number patterns of cluster P2 wereFigure 2 Genomic profiles of somatic copy number alterations (SCNA
Cluster P1 samples, RO1, RF, and LO4. (e, f) Cluster M samples, OM1, and O
M was similar to the pattern in cluster P1 except for a large deletion on ch
other clusters. red: amplification, blue: deletion.quite different from those of cluster P1 or M, supporting
the conclusion that clones in cluster P2 diverged earlier
than cluster M. Similar to the somatic mutation classifi-
cation, we classified “Common segments” when the
amplified/deleted segments were observed in all samples,
suggesting that the segments formed in the early phase
of tumorigenesis. Forty-four Common segments span-
ning 101 Mb were amplified, and 168 Common seg-
ments spanning 245 Mb were deleted. These segments
covered 354 genes and 1,835 genes, respectively. Then,
we characterized functional pathways affected by these
genes. The genes related to ‘skeletal system development’
were enriched in amplified Common segments, and those
related to ‘embryonic development ending in birth or egg
hatching’ and ‘chemokine signaling pathway’ were enriched
in deleted Common segments (Additional file 1: Table S7).
The segments were considered a “Shared segment” when
amplification or deletion was found in samples from any
two clusters. We determined that 154 Shared segments). (a) Common segments (green) and Shared segments (grey). (b, c, d)
M2. (g) Cluster P2 sample, LO3. Overall the pattern of SCNA in cluster
romosome X. Cluster P2 showed distinct SCNA patterns compared to
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(287 Mb) were deleted in both clusters P1 and M. Path-
ways previously reported to be altered in ovarian cancer,
such as the JAK/STAT signaling pathway and the
Cytokine-Cytokine Receptor pathway [24], were also
identified in these Shared segments, but not in the
Common segments. Interestingly, the genes related to
blood vessel morphogenesis (31 genes, Benjamin-
Hochberg (BH) score 0.094) were deleted Shared seg-
ments between cluster P1 and M, but not cluster P2. In
contrast, the genes related to hemophilic cell adhesion
(50 genes, BH score 9.9x10−16) were enriched in the
amplified segments found only in cluster P2.
Phylogenetic tree analysis based on somatic mutation
and copy number variation was used to study the clonal
relationship between different regions of primary and
metastatic tumors (Figure 3). The findings indicate that
metastatic lesions derive from a common, ancestral clone
within the primary tumor. In cases of bilateral ovarian tu-
mors like the one assessed here, metastatic potential may
be gained in the early stages of tumorigenesis.
Based on the SCNA data, we focused on the fre-
quently detected focal SCNA reported in the TCGA
data (Additional file 1: Table S8) [3]. Among the top 20
most frequently observed focal amplifications, 12 seg-
ments were altered in our study, and only MECOM,
TERT, and MYC segments were found among Common
amplified regions. Although regions containing KRAS,
ID4, MYCL1, and SOX17 were observed as tightly local-
ized amplification peaks, these peaks were observed
only clusters P1 and P2 for the patient in our study.
Also, among the top 20 most frequent focal deletions,
we found that 15% (3 of 20) of focal deletions including
RB1 and PPP2R2A were commonly observed in our pa-
tient. NF1 is one of the genes shown to be related to
intratumor heterogeneity in a previous study [5]. How-
ever, NF1 deletions were observed in both clusters in
our study. This finding suggests that intratumorFigure 3 Evolutionary model of non-spatial clustered metastatic ovar
copy number alteration).heterogeneity might appear differently in each patient.
Lastly, we annotated the copy number variation pat-
terns of 22 drug targets listed in the TCGA project for
this patient [3]. Although 15 targeted genes were altered
in this patient, only 40% (6 of 15) of the targeted genes
were altered in all clusters (Additional file 1: Table S9).
Discussion
Using NGS technology followed by confirmative valid-
ation, we were able to identify the clonal evolution of
multiple samples collected from both ovaries and meta-
static lesions in a single patient. Even though only 6% of
somatic mutations were present in all samples, the vast
majority of somatic variants found in the metastatic
samples were present in the primary tumor samples. All
11 cluster M-specific mutations were found in at least one
sample in cluster P1, and no somatic mutation was further
accumulated in cluster M. In addition, SCNA showed that
the genomic architecture of samples in cluster M were
similar to the patterns in cluster P1. These findings sug-
gest that peritoneal seeding arises with little accumulation
of somatic mutations and copy number alterations in this
patient. We also observed that non-spatial clusters of the
primary ovarian cancer samples (cluster P1 and P2) shared
a small number of genetic variations (Common mutations
and segments), which indicates that metastatic potential
developed at an early stage, and tumor clones in the peri-
toneal fluid were already able to implant in ovarian tissues
at that moment.
Our analysis demonstrated that all metastatic samples
from this patient were related to cluster P1, not P2, sug-
gesting that the metastatic ability of ancestry clones was
more accelerated in cluster P1. Based on this connec-
tion, we found that different cancer-related pathways
were altered in the early divergent clones (cluster P1 and
M vs. cluster P2). JAK/STAT signaling pathway genes in-
cluding JAK2, known to be related to tumor migration
through the epithelial-mesenchymal transition (EMT)ian cancer. (CCR: cytokine-cytokine receptor pathway, SCNA: somatic
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ing the hypothesis that clones in these clusters might be
under migration pressure. In contrast, genes involved in
cell adhesion pathways were only amplified in cluster P2,
indicating that the clones in cluster P2 might be under
an opposite pressure to clusters P1 and M.
Whether metastasis requires mutations beyond those
required to drive the primary tumor is controversial
[25]. In oropharyngeal squamous cell carcinoma, phylo-
genetic reconstruction according to somatic point muta-
tions showed that metastatic samples arose as a late
event [26]. In pancreatic cancer, seeding metastasis may
require driver mutations beyond those required for pri-
mary tumors, and phylogenetic trees across metastases
show organ-specific branches [27]. On the contrary, in
HGSC, peritoneal seeding may arise with little accumu-
lation of somatic mutations and copy number alter-
ations. We could not identify the known driver variants
causing transcoelomic metastasis in our patient.
In our study based on exome sequencing, all meta-
static clones (cluster M) diverged together at a late stage,
and the clusters of the primary tumor were distributed
in both ovaries (non-spatial clusters). Our results pro-
vide a clue that some clones in the primary tumor can
have metastatic potential, and that transcoelomic metas-
tasis might be a simple spreading process using existing
metastatic ability rather than supporting the previous
tumor evolution models (linear [28], parallel [29], or
mixed [30]). Regarding the clinical importance of trans-
coelomic metastasis in HGSC, it is surprising that few
additional mutations were found in peritoneal seeding
samples. This finding indicates the possibility that the
microenvironment, including factors such as stromal cells,
might play a role in fostering peritoneal implantation and
cancer cell growth by secreting inducing factors [31].
Our study may help to further our understanding of
tumor progression during HGSC. The data suggest that
clones in peritoneal implants may not be more resistant
than primary tumors in some patients. With the increas-
ing clinical use of bioinformatics, developing methods
that utilize the large amount of data to categorize pa-
tients into prognostic and treatment groups has become
increasingly important [32]. This study suggests that pat-
terns of intratumor heterogeneity between primary and
metastatic clones might be the key for identifying the
most appropriate treatment strategies for patients. In
cases with metastatic patterns similar to the patient in
this study (e.g., transcoelomic metastasis arising with lit-
tle genetic alteration accumulation compared with pri-
mary tumors), debulking surgery might be useful to
achieve optimal cytoreduction through adjuvant chemo-
therapy. If we identify those groups where seeding me-
tastasis may require driver mutations beyond those
required for primary tumorigenesis, debulking surgerymight not be useful. In these instances, we should focus
instead on the targeted therapy associated with driver
mutations in metastatic lesions.
This study may provide important information for those
who would like to evaluate tumor evolution in a larger co-
hort. For future studies evaluating clonal evolution in epi-
thelial ovarian cancer, the following should be considered.
First, the presence of mutations identified concurrently in
most samples should be validated in a large number of co-
horts in order to identify the key regulators in early
tumorigenesis. Second, the clonal relationship between
various metastatic sites from peritoneal seeding should be
evaluated to identify the role of the microenvironment.
Further studies are required to document the differences
in genomic profiles between various metastatic sites such
as the omentum, diaphragm, spleen, and pelvic periton-
eum. This approach may elucidate the key regulators in
the distinct metastatic characteristics of epithelial ovarian
cancer. Third, genomic alterations other than somatic mu-
tations and copy number changes should be considered to
identify the unveiled driver variant causing tumor progres-
sion. Recently, the microRNA expression profile of an
omental metastatic tumor was found to differ from that of
the primary tumor in epithelial ovarian cancer, suggesting
that microRNA might play role in tumor progression in
metastatic tissues [33]. Another group reported that the
genomic rearrangement landscapes of metastatic lesions
differ from those of primary ovarian cancer [34].
Conclusion
We performed whole exome sequencing and copy num-
ber analysis for multiple primary and metastatic samples
within an individual patient. Our research showed that
HGSC has diverse intratumor heterogeneity in terms of
somatic mutation and copy number variation profiles,
but transcoelomic metastasis arises with little accumula-
tion of genetic alterations in this patient.
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